Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ceapro Inc
(OP:
CRPOF
)
N/A
UNCHANGED
Last Price
Updated: 11:58 AM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1700
Today's Range
N/A - N/A
52wk Range
0.1146 - 0.3140
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aeterna Zentaris and Ceapro Complete Merger Transaction
June 03, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 29, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Performance
More News
Read More
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
April 29, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
March 28, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
March 12, 2024
From
Ceapro Inc.; Aeterna Zentaris Inc.
Via
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
February 26, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
February 23, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
February 15, 2024
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
December 13, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
November 29, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
November 27, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
November 07, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
August 29, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
August 25, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
July 18, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Announces Results of 2023 Shareholders’ Meeting
June 07, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
May 25, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
May 23, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
May 03, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
April 27, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
April 12, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International Conference
March 23, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society
March 08, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
February 21, 2023
From
Ceapro Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.